Rakovich et al. demonstrated that QD conjugation with a single variable domain of anti-HER2 antibodies can be successfully used for the immunolabeling of breast cancer cells and represents a potential biomarker that is more sensitive than conventional IHC [162]. This evidence concerns the gene ERBB2 and breast carcinoma.